Showing 2931-2940 of 4063 results for "".
- Prevent Blindness Names Ed Buffington, GPN Technologies, as the 2024 Person of Vision Award Recipienthttps://modernod.com/news/prevent-blindness-names-ed-buffington-gpn-technologies-as-the-2024-person-of-vision-award-recipient/2481856/Prevent Blindness announced that the
- Inventors of OCT Named Winners of 2023 Lasker Awardshttps://modernod.com/news/inventors-of-oct-named-winners-of-2023-lasker-awards/2481841/The
- Haag-Streit to Present Ophthalmic Skills Training Center Concept at ESCRS 2023https://modernod.com/news/haag-streit-to-present-ophthalmic-skills-training-center-concept-at-escrs-2023/2481783/Haag-Streit announced it is showcasing the 'Ophthalmic Skills Training Center (OSTC)' at this year's Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). At the core of the Ophthalmic Skills Training Center is the combination of
- Optometry Giving Sight Kicks Off 2023 World Sight Day Challengehttps://modernod.com/news/optometry-giving-sight-kicks-off-2023-world-sight-day-challenge/2481779/To support its mission to eradicate uncorrected refractive error through the growth and expansion of optometry around the world,
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107https://modernod.com/news/asclepix-therapeutics-raises-10-million-to-advance-phase-12a-clinical-study-of-axt107/2481749/AsclepiX Therapeutics announced that it has secured a $10 million Series A-3 financing to advance clinical development of its lead candidate, AXT107 (gersizangitide), in patients with wet AMD. “With the completion of this round, we are excited to embark into the next phase of
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Alcon Expands Plastic Bank Partnership in 2023 to Further Support Sustainability Effortshttps://modernod.com/news/alcon-expands-plastic-bank-partnership-in-2023-to-further-support-sustainability-efforts/2481591/Alcon announced the expansion of the partnership with Plastic Bank—an organization that builds recycling ecosystems in under-developed communities to fight plastic pollution while providing collection members with a path out of poverty. For each ton of plastic introduced in the marketp
- Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 ASCRShttps://modernod.com/news/sight-sciences-glaucoma-and-dry-eye-technologies-to-be-featured-in-multiple-clinical-presentations-at-the-2023-ascrs/2481590/Sight Sciences announced that two of its proprietary glaucoma and dry eye technologies, the Omni Surgical System and the TearCare System, will be featured in oral presentations and one poster at this year's ASCRS annual meeting in San Diego. The Omni Surgical System technology
- Registration Now Open for Neuro-Optometric Rehabiliation Association 2023 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabiliation-association-2023-conference/2481568/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 33rd annual conference, October 5-8, at the Portland Marriot Downtown Waterfront in Portland, Oregon. The NORA annual conference is an event for eye care and other health care
- Ocugen to Present on Modifier Gene Therapy Platform at ARVO 2023https://modernod.com/news/ocugen-to-present-on-modifier-gene-therapy-platform-at-arvo-2023/2481547/Ocugen announced that the company will present on its modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis; OCU410 for the treatment dry age-related macular degeneration (dry AMD); OCU410ST for the treatment of St